Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]

Keohane C, Radia DH, Harrison CN. Biologics: Targets and Therapy. 2013;7:189–198. On page 193 note that the paragraph beginning "Pacritinib (SB1518; Cell Technology, Inc, Mountain View, CA, USA) is a JAK2 and FLT3 inhibitor currently being evaluated at a dose of 400 mg daily in a Phas...

Full description

Bibliographic Details
Main Authors: Keohane C, Radia DH, Harrison CN
Format: Article
Language:English
Published: Dove Medical Press 2013-10-01
Series:Biologics: Targets & Therapy
Online Access:http://www.dovepress.com/corrigendum-treatment-and-management-of-myelofibrosis-in-the-era--a14840